Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Male

• aged 50 years or older

• a diagnostic claim for BPH

• at least one prescription claim for a 5ARI or AB in the enrollment period

• continuous eligibility for 6 months prior to and 12 months after index prescription date

Exclusion Criteria:

• diagnosis of prostate or bladder cancer during the study period

• any prostate-related surgical procedure within 1 month of the index prescription date

• prescription claim for finasteride 1 mg for male pattern baldness during the study period